

For further information contact:
Dr Paul D'Sylva
CEO
Commonwealth Biotechnologies, Inc.
858 699 0298

Commonwealth Biotechnologies, Inc. Completes Acquisition of Tripos Discovery Research Ltd

Richmond, VA (June 6, 2007). Commonwealth Biotechnologies, Inc (CBI), (NASDAQ: "CBTE") today announced that it has completed the acquisition of all of the outstanding capital stock of Tripos Discovery Research Limited, an English limited company ("TDR"). TDR is a world leader in medicinal and combinatorial chemistry and provides products and services that are complementary to CBI's existing offerings in biologics and custom peptides. The TDR acquisition provides CBI with a strategic production and sales and marketing site in the United Kingdom and is designed to accelerate the CBI's revenue and earnings growth. On a pro-forma basis, the acquisition of TDR represents an increase in CBI's 2006 revenues to \$16.4 million and upon closing increases CBI's cash position to \$5.36 million.

CBI's CEO, Dr Paul D'Sylva said, "CBI's acquisition of TDR is in line with our company's strategy to expand its drug discovery and development services in the field of pre-clinical chemistry and to extend the sale of its full suite of products and services into Europe. With the additional technical and commercial capabilities and resources that TDR brings, CBI anticipates that it will be able to grow a powerful, robust and diverse drug discovery services franchise servicing the growing global drug discovery market. Immediate cost and revenue synergies are expected from this transaction, which will accelerate CBI's continued growth."

Under the terms of the transaction, which was unanimously approved by CBI's Board of Directors, CBI has acquired all of the outstanding capital stock of TDR for an up-front payment of \$350,000 followed by payments of up to \$1.8 million from TDR receivables and billings. Concurrent with this transaction, TDR is entering into a sale-leaseback transaction with the South West of England Regional Development Authority ("SWERDA") for a 12 year lease of the facilities in Bude renewable every 3 years, and has been released from grant repayment obligations with the English Department of Trade and Industry and various inter-company advances from TDR's former parent organization, Tripos, Inc., a Utah corporation.

CBI's Chairman Dr Richard Freer said, "TDR is widely acknowledged as one of the premier drug discovery service companies in the world. With this transaction, the CBI group now offers comprehensive discovery products and services across the three major drug classes of biologics, peptides and small molecules. We at CBI are very excited about the potential this transaction has to grow our top line revenue and bottom line result."

About Tripos Discovery Research Limited

Tripos Discovery Research Ltd (“TDR”) is a leading knowledge driven, drug discovery services business that provides pharmaceutical and biotechnology companies with novel approaches to drug discovery. Applying proprietary computational design and therapeutic medicinal chemistry tools and expertise, TDR is able to reduce drug discovery timelines by up to 30%. Since 1997, TDR has been offering compound libraries under the LeadQuest® brand, screening libraries under the LeadScreen® brand and custom de novo compound libraries under the LeadSelect® brand.

About Commonwealth Biotechnologies, Inc

The CBI group offers cutting-edge R&D products and services to the global life sciences industry. CBI now operates four distinct business units: (1) CBI Services, a discovery phase contract research organization, (2) Fairfax Identity Laboratories, a DNA reference business; (3) Mimotopes, a peptide and discovery chemistry business; and (4) TDR, a medicinal and synthetic discovery chemistry business. Collectively, CBI companies employ over 140 staff in world-class laboratories in the U.S., U.K., and Australia.

Forward Looking Statements

The statements contained in this press release that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities and Exchange Act of 1934, as amended, including statements regarding CBI’s expectations, beliefs, intentions or strategies regarding the future. Forward-looking statements include, but are not limited to, express or implied statements regarding future revenues, revenue growth and profitability, and the markets for its services. All forward-looking statements included in this press release are based upon information available to CBI as of the date hereof. CBI assumes no obligation to update any such forward-looking statements. Forward-looking statements involve risks and uncertainties, which could cause actual results to differ materially from those projected. Actual results may differ materially due to a number of factors including the perceived need for CBI’s services, CBI’s ability to efficiently incorporate TDR into its operations and macro economic conditions. These and other risks relating to CBI’s business are set forth in CBI’s Form 10-KSB filed with the Securities and Exchange Commission on March 30, 2007, and CBI’s Form 10-QSBs and other reports filed from time to time with the Securities and Exchange Commission.